109 related articles for article (PubMed ID: 17724740)
41. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Abergel A; Hezode C; Leroy V; Barange K; Bronowicki JP; Tran A; Alric L; Castera L; Bernard PH; Henquell C; Lafeuille H; Ughetto S; Darcha C; Chevallier M; Martineau N; Dubost S; Randl K; Dhumeaux D; Bommelaer G; Bonny C;
J Viral Hepat; 2006 Dec; 13(12):811-20. PubMed ID: 17109680
[TBL] [Abstract][Full Text] [Related]
42. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
43. [Cognitive disturbances observed in chronic hepatitis C patients during pegylated interferon alpha and ribavirin therapy].
Pawełczyk T; Pawełczyk A; Białkowska J; Jabłkowski M; Strzelecki D; Dworniak D; Rabe-Jabłońska J
Psychiatr Pol; 2008; 42(6):925-41. PubMed ID: 19441669
[TBL] [Abstract][Full Text] [Related]
44. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.
Alves Couto C; Costa Faria L; Dias Ribeiro D; de Paula Farah K; de Melo Couto OF; de Abreu Ferrari TC
Liver Int; 2006 Dec; 26(10):1294-7. PubMed ID: 17105597
[TBL] [Abstract][Full Text] [Related]
45. Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin.
Miura Y; Kami M; Yotsuya R; Toda N; Komatsu T
Am J Hematol; 2008 Sep; 83(9):758-9. PubMed ID: 18615552
[No Abstract] [Full Text] [Related]
46. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial.
Jonas MM; Balistreri W; Gonzalez-Peralta RP; Haber B; Lobritto S; Mohan P; Molleston JP; Murray KF; Narkewicz MR; Rosenthal P; Schwarz KB; Barton BA; Shepherd JA; Mitchell PD; Duggan C
Hepatology; 2012 Aug; 56(2):523-31. PubMed ID: 22383118
[TBL] [Abstract][Full Text] [Related]
47. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
[TBL] [Abstract][Full Text] [Related]
48. De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.
Tovar JL; Buti M; Segarra A; Majó J; Esteban R
Int Urol Nephrol; 2008; 40(2):539-41. PubMed ID: 17987400
[TBL] [Abstract][Full Text] [Related]
49. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.
van Zonneveld M; Flink HJ; Verhey E; Senturk H; Zeuzem S; Akarca US; Cakaloglu Y; Simon C; So TM; Gerken G; de Man RA; Hansen BE; Schalm SW; Janssen HL;
Aliment Pharmacol Ther; 2005 May; 21(9):1163-71. PubMed ID: 15854180
[TBL] [Abstract][Full Text] [Related]
50. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C.
Uchida M; Hamada A; Yamasaki M; Fujiyama S; Sasaki Y; Saito H
Drug Metab Pharmacokinet; 2004 Dec; 19(6):438-43. PubMed ID: 15681898
[TBL] [Abstract][Full Text] [Related]
51. Rosacea fulminans related to pegylated interferon alpha-2b and ribavirin therapy.
Bettoli V; Mantovani L; Boccia S; Virgili A
Acta Derm Venereol; 2006; 86(3):258-9. PubMed ID: 16710591
[No Abstract] [Full Text] [Related]
52. Interstitial pneumonitis during combination therapy with interferon-alpha and ribavirin in a patient with chronic Hepatitis C.
Rothfuss KS; Bode JC
Z Gastroenterol; 2002 Sep; 40(9):807-10. PubMed ID: 12215950
[TBL] [Abstract][Full Text] [Related]
53. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
[TBL] [Abstract][Full Text] [Related]
54. [EFFECTS OF URSODEOXYCHOLIC ACID IN STANDART INTERFERONTHERAPY OF PATIENTS WITH CHRONIC HEPATITIS C AND B].
Kurmanova GM; Kurmanova KB; Sadykova ShS
Eksp Klin Gastroenterol; 2015; (8):99-104. PubMed ID: 27017752
[TBL] [Abstract][Full Text] [Related]
55. Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.
Carrillo-Esper R; González-Avila D; Uribe-Ríos M; Méndez-Sánchez N
Ann Hepatol; 2008; 7(1):87-90. PubMed ID: 18376374
[TBL] [Abstract][Full Text] [Related]
56. Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient.
Johnson K; Sargent LA; Galizio C; Ubogu EE
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1110-4. PubMed ID: 19047844
[TBL] [Abstract][Full Text] [Related]
57. Repeated episodes of fixed eruption 3 months after discontinuing pegylated interferon-alpha-2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Sato M; Sueki H; Iijima M
Clin Exp Dermatol; 2009 Dec; 34(8):e814-7. PubMed ID: 19817760
[TBL] [Abstract][Full Text] [Related]
58. [Alterations within white blood cell subsets in children with chronic viral hepatitis C before treatment with pegylated interferon and ribavirin].
Mozer-Lisewska I; Dworacki G; Kaczmarek E; Słuzewski W; Kowala-Piaskowska A; Figlerowicz M; Kaczmarek M; Zeromski J
Przegl Epidemiol; 2005; 59(2):483-9. PubMed ID: 16190557
[TBL] [Abstract][Full Text] [Related]
59. Dilated cardiomyopathy and hypothyroidism associated with pegylated interferon and ribavirin treatment for chronic hepatitis C: case report and literature review.
Zhao W; Ji F; Yu S; Li Z; Deng H
Braz J Infect Dis; 2014; 18(1):110-3. PubMed ID: 24120833
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C.
Tod M; Farcy-Afif M; Stocco J; Boyer N; Bouton V; Sinègre M; Marcellin P
Clin Pharmacokinet; 2005; 44(4):417-28. PubMed ID: 15828854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
